bioAffinity Technologies, Inc. (NASDAQ:BIAF) Short Interest Up 107.6% in March

bioAffinity Technologies, Inc. (NASDAQ:BIAF) was the recipient of a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 239,800 shares, a growth of 107.6% from the February 28th total of 115,500 shares. Based on an average daily trading volume, of 261,100 shares, the days-to-cover ratio is presently 0.9 days. Approximately 2.6% of the shares of the company are short sold.

bioAffinity Technologies Stock Down 3.2 %

Shares of BIAF stock opened at $0.26 on Friday. bioAffinity Technologies has a twelve month low of $0.25 and a twelve month high of $3.16. The stock has a market cap of $4.08 million, a P/E ratio of -0.32 and a beta of 3.12. The stock has a 50 day moving average of $0.57 and a 200 day moving average of $1.08. The company has a current ratio of 1.02, a quick ratio of 1.01 and a debt-to-equity ratio of 0.18.

Institutional Investors Weigh In On bioAffinity Technologies

A hedge fund recently raised its stake in bioAffinity Technologies stock. Sheaff Brock Investment Advisors LLC boosted its position in shares of bioAffinity Technologies, Inc. (NASDAQ:BIAF) by 131.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 46,304 shares of the company’s stock after buying an additional 26,304 shares during the quarter. Sheaff Brock Investment Advisors LLC owned approximately 0.30% of bioAffinity Technologies worth $42,000 at the end of the most recent reporting period. 1.64% of the stock is currently owned by institutional investors.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.